Albino A P, Fountain J W
Mammalian Cell Transformation Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021.
Cancer Treat Res. 1993;65:201-55. doi: 10.1007/978-1-4615-3080-0_8.
Due to a variety of known and unknown control mechanisms, the human genome is remarkably stable when compared to most other species. The long latency periods of most solid tumors, during which the cell undergoes malignant transformation, are presumably due to this stability. The molecular basis responsible for the induction of genetic instability and the resultant biological characteristics manifest in tumor populations is not well understood. The discovery of both oncogenes and tumor suppressor genes, however, has placed the phenomenon of human genome stability on a more solid conceptual footing. These types of genes clearly place multiple barriers to oncogenic transformation, and traversing these barriers apparently requires both time and the accumulation of genetic defects that cannot be corrected. The evolution of neoplasias can, therefore, be predicted to be due to: (1) consistent and progressive loss of tumor suppressor genes; (2) gene amplification, resulting in the over-expression of proteins that aid in tumor progression; (3) gene mutation, which alters the orderly biochemistry of the normal cell; (4) genes that allow a cell like the melanocyte to escape the confining nature of the epidermis and to invade through the dermis into the circulatory and lymphatic systems in order to disseminate itself to other organs (e.g., proteolytic enzymes, enzyme inhibitors, integrins, metastases genes, chemotactic factors etc.); (5) factors, perhaps such as TGF beta 2, that may impact negatively on MHC antigens and confuse host defense mechanisms; and (6) S.O.S.-type genes, which may be expressed as a direct response to the accumulating damage in an attempt to correct the damage, but that may then become part of the problem instead of the solution. The extraordinary plasticity and instability of the genome of a melanoma cell suggests an inordinate amount of genetic flux. In addition to activating and inactivating various genes, this constant shuffling and rearranging of the genome in neoplasms such as MM may be constantly altering gene dose. Cytogenetic and molecular biological studies have been the Rosetta stone for understanding the etiological relevant genetic events in human cancers. Genetic alterations fundamental to the pathology of MM have begun to be defined. Studies designed to understand these perturbations at the biochemical and organismic level are underway.(ABSTRACT TRUNCATED AT 400 WORDS)
由于多种已知和未知的调控机制,与大多数其他物种相比,人类基因组具有显著的稳定性。大多数实体瘤的潜伏期很长,在此期间细胞发生恶性转化,这大概归因于这种稳定性。导致遗传不稳定的诱导以及肿瘤群体中所表现出的相应生物学特性的分子基础尚未完全明了。然而,癌基因和肿瘤抑制基因的发现,已将人类基因组稳定性现象置于更坚实的概念基础之上。这些类型的基因显然对致癌转化设置了多重障碍,跨越这些障碍显然既需要时间,也需要累积无法纠正的遗传缺陷。因此,可以预测肿瘤的发生发展归因于:(1)肿瘤抑制基因持续且渐进性缺失;(2)基因扩增,导致有助于肿瘤进展的蛋白质过度表达;(3)基因突变,改变正常细胞有序的生物化学过程;(4)使黑素细胞样细胞能够摆脱表皮的限制特性,并通过真皮侵入循环和淋巴系统以便扩散至其他器官的基因(例如蛋白水解酶、酶抑制剂、整合素、转移基因、趋化因子等);(5)可能对MHC抗原产生负面影响并混淆宿主防御机制的因子,如转化生长因子β2;以及(6)可能作为对累积损伤的直接反应而表达以试图纠正损伤,但随后可能成为问题而非解决方案一部分的S.O.S. 型基因。黑色素瘤细胞基因组的非凡可塑性和不稳定性表明存在大量的基因通量。除了激活和失活各种基因外,在诸如黑色素瘤等肿瘤中基因组这种持续的重排和重新排列可能会不断改变基因剂量。细胞遗传学和分子生物学研究一直是理解人类癌症病因相关遗传事件的关键所在。黑色素瘤病理学的基础遗传改变已开始得到明确。旨在从生物化学和机体水平理解这些扰动的研究正在进行中。(摘要截选至400字)